Leukemia Research
Volume 29, Issue 7 , Pages 813-820, July 2005

Expression of mRNA and proteins for toll-like receptors, associated molecules, defensins and LL-37 by SRIK-NKL, a CD8+ NK/T cell line

  • Maya D. Srivastava

      Affiliations

    • Department of Allergy and Immunology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 216 444 6933; fax: +1 440 684 0928; pager: +1 800 329 3709.
  • ,
  • B.I.S Srivastava

      Affiliations

    • Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

Received 11 July 2004; accepted 17 December 2004. published online 07 March 2011.

Abstract 

Natural killer (NK) cells, innate lymphocyte effectors, kill virus-infected host and tumor cells in non-MHC, non-TCR restricted fashion, unlike T cells. The role of NK cells in recognition and killing of pathogens remains unknown. Expression of the ten human pathogen associated molecular pattern or toll-like receptors (TLR's), associated molecules, and antimicrobial peptides α, β defensins, and LL-37 by NK cells has not been investigated previously. We report our CD8+ NK/T cell line SRIK-NKL, derived from leukemic phase of acute lymphoblastic lymphoma, expresses mRNA and protein for 8/10 TLR's, associated proteins for signaling, defensins, cathelicidin/LL-37, and responds to live bacteria by cell proliferation and increased IFN-γ, TNF-α, TNF-β, and MIP-1α production.

Keywords: Natural killer cell, Innate immunity, Defensin, Toll-like receptor, Cathelicidin, CD8, Leukemia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(05)00034-2

doi:10.1016/j.leukres.2004.12.016

Leukemia Research
Volume 29, Issue 7 , Pages 813-820, July 2005